How much funding has Sana Biotechnology raised?

Sana Biotechnology has raised $1.4B in total funding, most recently a Series D round.

Who are Sana Biotechnology's investors?

Sana Biotechnology's investors include ARCH Venture Partners, Flagship Pioneering, SoftBank, F-Prime Capital, Canada Pension Plan Investment Board, Baillie Gifford.

When was Sana Biotechnology founded?

Sana Biotechnology was founded in 2018.

Where is Sana Biotechnology headquartered?

Sana Biotechnology is headquartered in Seattle, Washington, United States.

What industry is Sana Biotechnology in?

Sana Biotechnology operates in Biotech, Healthcare, Life Sciences, Therapeutics.

How many employees does Sana Biotechnology have?

Sana Biotechnology has 201-500 employees.

Sana Biotechnology

IPO

Engineered cells as medicines

Public · Seattle, United States · Founded 2018 · $1.4B raised

Headquarters: Seattle, Washington
Employees: 201–500
Founded: 2018
Business Model: B2B
Website: sana.com

Total Funding: $1.4B
Last Round: $821.0M Series DJun 2020
Rounds: 5
Type: Public

About

Sana Biotechnology is focused on creating engineered cells as medicines to repair and control genes or replace damaged cells, targeting diseases like diabetes, B-cell cancers, and autoimmune disorders. With operations in Seattle, Cambridge, and South San Francisco, Sana leverages expertise in cell and gene therapy to develop curative therapies.

Summary

Sana Biotechnology is a Biotech company based in Seattle, United States, founded in 2018. It has raised $1.4B in total across 5 rounds, most recently a $821.0M Series D round in Jun 2020. Investors include ARCH Venture Partners, Flagship Pioneering and SoftBank.